Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release injectable naltrexone as adjunct therapy to prevent substance use in patients with substance use disorder receiving ADHD treatment
2016-004710-95Phase 2Terminated
- Sponsor
- Beroendecentrum Stockholm
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in amphetamine dependence, substance use disorder (SUD) and attention deficit hyperactivity disorder (ADHD) comparing XR-NTX extended-release naltrexone with Placebo injection (2 arms). Primary endpoint: Proportion of urine samples free of drugs of abuse (primary, including handling of missing urine data). Started Jan 2017; status: terminated.
02
Drugs
naltrexone
03
Conditions
amphetamine dependencesubstance use disorder (SUD)attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2016-004710-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004710-95.